NEJM:高水平的血液循环因子suPAR可增加慢性肾病的发病风险

2015-11-06 sunshine 译 MedSci原创

目前已知,血浆中可溶性尿激酶受体(suPAR)的水平较高与患者局灶性节段性肾小球硬化及较差的临床结果有关。对于肾功能正常的患者其血浆中suPAR的水平升高是否与日后肾小球滤过率(eGFR)下降及慢性肾病的发生有关则尚未可知。 本研究共纳入了3683名患者(平均年龄:63岁;65%为男性,suPAR的水平中位数为3040 pg/ml),评估其血浆中的suPAR水平,并在随访期间评估了2292名

目前已知,血浆中可溶性尿激酶受体(suPAR)的水平较高与患者局灶性节段性肾小球硬化及较差的临床结果有关。对于肾功能正常的患者其血浆中suPAR的水平升高是否与日后肾小球滤过率(eGFR)下降及慢性肾病的发生有关则尚未可知。

本研究共纳入了3683名患者(平均年龄:63岁;65%为男性,suPAR的水平中位数为3040 pg/ml),评估其血浆中的suPAR水平,并在随访期间评估了2292名患者的肾功能。使用线性混合模型和Cox回归模型分析基线时期suPAR的水平与eGFR之间的关系,eGFR随时间的变化情况以及机体慢性肾病的发生情况。

结果发现,基线时期suPAR的水平越高,随访期间患者eGFR下降的程度越高;suPAR水平四分位数最低的患者其eGFR每年的变化为−0.9 ml/(min/1.73 m2体表面积),而suPAR水平四分位数最高的患者其eGFR每年的变化为−4.2 ml/(min/1.73 m2体表面积)。基线时期eGFR正常(≥90ml/(min/1.73 m2体表面积))的921名患者其suPAR相关的eGFR下降程度最高。基线时期eGFR ≥60ml/(min/1.73 m2体表面积)的1335名患者中,suPAR水平四分位数最高的患者进展为慢性肾病的风险相当于四分位数最低患者的3.13倍。

总而言之,本研究表明,较高水平的suPAR与慢性肾病的发生独立相关,并可加快eGFR的下降速度。

原始出处:

Salim S. Hayek,, Sanja Sever, et al. Soluble Urokinase Receptor and Chronic Kidney Disease. NEJM.November 5, 2015DOI: 10.1056/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18149, encryptionId=31251814945, topicName=uPAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Dec 05 14:53:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028283, encodeId=c2ed202828337, content=<a href='/topic/show?id=5664892e2d9' target=_blank style='color:#2F92EE;'>#血液循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89272, encryptionId=5664892e2d9, topicName=血液循环)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Oct 04 12:53:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56926, encodeId=2f48569264d, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 15:33:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42722, encodeId=e4b842e222a, content=这也能发表NEJM? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 07 09:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42676, encodeId=3e93426e61e, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b71655754, createdName=科研屌丝, createdTime=Fri Nov 06 18:45:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2015-12-05 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18149, encryptionId=31251814945, topicName=uPAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Dec 05 14:53:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028283, encodeId=c2ed202828337, content=<a href='/topic/show?id=5664892e2d9' target=_blank style='color:#2F92EE;'>#血液循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89272, encryptionId=5664892e2d9, topicName=血液循环)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Oct 04 12:53:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56926, encodeId=2f48569264d, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 15:33:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42722, encodeId=e4b842e222a, content=这也能发表NEJM? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 07 09:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42676, encodeId=3e93426e61e, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b71655754, createdName=科研屌丝, createdTime=Fri Nov 06 18:45:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18149, encryptionId=31251814945, topicName=uPAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Dec 05 14:53:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028283, encodeId=c2ed202828337, content=<a href='/topic/show?id=5664892e2d9' target=_blank style='color:#2F92EE;'>#血液循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89272, encryptionId=5664892e2d9, topicName=血液循环)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Oct 04 12:53:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56926, encodeId=2f48569264d, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 15:33:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42722, encodeId=e4b842e222a, content=这也能发表NEJM? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 07 09:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42676, encodeId=3e93426e61e, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b71655754, createdName=科研屌丝, createdTime=Fri Nov 06 18:45:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2016-01-13 Lynee劲飞扬

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18149, encryptionId=31251814945, topicName=uPAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Dec 05 14:53:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028283, encodeId=c2ed202828337, content=<a href='/topic/show?id=5664892e2d9' target=_blank style='color:#2F92EE;'>#血液循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89272, encryptionId=5664892e2d9, topicName=血液循环)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Oct 04 12:53:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56926, encodeId=2f48569264d, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 15:33:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42722, encodeId=e4b842e222a, content=这也能发表NEJM? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 07 09:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42676, encodeId=3e93426e61e, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b71655754, createdName=科研屌丝, createdTime=Fri Nov 06 18:45:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2015-11-07 lovetcm

    这也能发表NEJM?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2024586, encodeId=109f202458614, content=<a href='/topic/show?id=31251814945' target=_blank style='color:#2F92EE;'>#uPAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18149, encryptionId=31251814945, topicName=uPAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Sat Dec 05 14:53:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028283, encodeId=c2ed202828337, content=<a href='/topic/show?id=5664892e2d9' target=_blank style='color:#2F92EE;'>#血液循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89272, encryptionId=5664892e2d9, topicName=血液循环)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Oct 04 12:53:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56926, encodeId=2f48569264d, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 15:33:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42722, encodeId=e4b842e222a, content=这也能发表NEJM? <br> , beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Nov 07 09:07:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42676, encodeId=3e93426e61e, content=好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b71655754, createdName=科研屌丝, createdTime=Fri Nov 06 18:45:00 CST 2015, time=2015-11-06, status=1, ipAttribution=)]
    2015-11-06 科研屌丝

    好文

    0

相关资讯

JASN:血液循环因子suPAR或与引发肾衰竭原因相关联

2012年11月26日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Journal of the American Society of Nephrology (JASN)上的一篇研究报告中,来自拉什大学医学中心的研究者表示,易患肾脏衰竭的病人,其更易于在血液循环中存在高水平的特殊因子。这项研究揭示了这种特殊因子可以用于监测病人的疾病发病进展以及病人对不同疗法的反应,其或许也是未来治疗难治性